Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9713MR)

This product GTTS-WQ9713MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9713MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ827MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ10972MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ11023MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ4303MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ1957MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ1719MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ15661MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ15550MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW